Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.

Only more recently has it been realized that the intense effort to care for and cure a child with cancer does not end with survival. Continued surveillance and a variety of interventions may, in many cases, be needed to identify and care for consequences of treatment that can appear early or only after several decades and impair survivors' health and quality of life. The more than two-thirds of childhood cancer survivors who experience late effects-that is, complications, disabilities, or adverse outcomes-as a result of their disease, its treatment, or both, are the focus of this report which outlines a comprehensive policy agenda that links improved health care delivery and follow-up, investments in education and training for health care providers, and expanded research to improve the long-term outlook for this growing population now exceeding 270,000 Americans.

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

The treatment of childhood cancer has become increasingly successful over the last forty years, and during the last two decades in particular, and the overall cure rate is now 60-70%. This, in turn, has introduced new issues for the clinician as the number of long-term survivors has increased. Some of the therapies that have contributed most to the improvement in survival are now known to have serious consequences for the patient in later life, and many survivors will be affected by physical, educational and psychological disability to a lesser or greater degree. This definitive reference brings together all aspects of long-term effects of treatment for cancer during childhood in a single comprehensive volume. International in perspective, the book is structured according to complication rather than original site of malignancy for ease of reference. Topics covered include problems in the neurological system and special senses of sight and sound, cardiovascular, respiratory, gastrointestinal, urological and musculoskeletal complications, effects on the endocrine system and, in particular, future fertility, and secondary cancers. The book also reviews in detail the important issues of quality of life, prevention initiatives and strategies for long-term follow up. Key point summaries are included throughout, and the references are annotated to guide the reader quickly to seminal primary papers and key review articles. With an accessible and consistent approach throughout, Late Effects of Childhood Cancer is an invaluable source of information and guidance for pediatric oncologists, who need to keep fully informed in order to advise patients and their parents appropriately, and also for pediatric and adult endocrinologists, adult oncologists and other physicians to whom the patient with late effects may initially present.

More than 325,000 children, teens, and adults in the United States are survivors of childhood cancer. The surgery, radiation, chemotherapy, and stem cell transplants used to cure children can affect growing bodies and developing minds. If survivors know of these potential problems, they can take steps to identify, cope with, or treat them early if they do develop. The third edition of Childhood Cancer Survivors charts the territory for survivors by providing state-of-the-art information about: " Medical late effects from treatment " Emotional aspects of surviving cancer " Schedules for follow-up care " Challenges in the heath-care system " Lifestyle choices to maximize health " Discrimination in employment or insurance Woven throughout the text are stories from more than 100 survivors and parents. Authors Keene, Hobbie, and Ruccione are experts in the field of childhood cancer. Keene is the mother of a survivor of childhood leukemia and the author of several books including Childhood Leukemia, Childhood Cancer, Educating the Child with Cancer, and Chemo, Craziness & Comfort. Hobbie is Associate Director of the Cancer Survivorship Program at Children's Hospital of Philadelphia. Ruccione is Co-Director of the HOPE (Hematology-Oncology Psychosocial and Education) Program in the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles.

Established since 1986 as the definitive text and reference on use of radiation therapy for childhood cancer, Pediatric Radiation Oncology is now in its thoroughly revised and updated Fifth Edition. This edition reviews all significant recent clinical trials—including, for the first time, significant European clinical trials—and provides increased coverage of international and Third World issues. The latest cancer staging guidelines are included. New chapters cover psychosocial aspects of radiotherapy for the child and family and medical management of pain, nausea, nutritional problems, and blood count depression in the child with cancer. This edition also has full-color illustrations throughout. A companion website includes the full text and an image bank.

The seventh edition of Brook's Clinical Pediatric Endocrinology has been compiled by an experienced editorial team and internationally renowned contributors; it presents basic science and clinical management of endocrine disorders for all involved in the care of children and adolescents. It provides treatments for a variety of hormonal diseases, including diabetes and hypoglycaemia, growth problems, thyroid disease and disorders of puberty, sexual differentiation, calcium metabolism, steroid metabolism and hypopituitarism.